MX2023005342A - Métodos para tratar padecimientos relacionados con el receptor s1p1. - Google Patents

Métodos para tratar padecimientos relacionados con el receptor s1p1.

Info

Publication number
MX2023005342A
MX2023005342A MX2023005342A MX2023005342A MX2023005342A MX 2023005342 A MX2023005342 A MX 2023005342A MX 2023005342 A MX2023005342 A MX 2023005342A MX 2023005342 A MX2023005342 A MX 2023005342A MX 2023005342 A MX2023005342 A MX 2023005342A
Authority
MX
Mexico
Prior art keywords
sub
methods
receptor
conditions related
treating conditions
Prior art date
Application number
MX2023005342A
Other languages
English (en)
Inventor
Gurpreet Ahluwalia
Andrew Christopher Wesley Selfridge
Maple Fung
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2023005342A publication Critical patent/MX2023005342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen en la presente métodos para tratar la dermatitis atópica que permite para el tratamiento efectivo de la enfermedad con un período de interrupción si se observan ciertos eventos adversos. Adicionalmente, se describen aquí nuevos métodos para tratar la dermatitis atópica de moderada a grave.
MX2023005342A 2020-11-09 2021-11-08 Métodos para tratar padecimientos relacionados con el receptor s1p1. MX2023005342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063111312P 2020-11-09 2020-11-09
PCT/US2021/058483 WO2022099150A1 (en) 2020-11-09 2021-11-08 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2023005342A true MX2023005342A (es) 2023-09-19

Family

ID=81456736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005342A MX2023005342A (es) 2020-11-09 2021-11-08 Métodos para tratar padecimientos relacionados con el receptor s1p1.

Country Status (9)

Country Link
US (1) US20230414567A1 (es)
EP (1) EP4240349A1 (es)
JP (1) JP2023548474A (es)
KR (1) KR20230106644A (es)
CN (1) CN116887826A (es)
CA (1) CA3200998A1 (es)
IL (1) IL302816A (es)
MX (1) MX2023005342A (es)
WO (1) WO2022099150A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
WO2023214312A1 (en) * 2022-05-06 2023-11-09 Arena Pharmaceuticals, Inc. Methods of treating atopic dermatitis with etrasimod

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730500C (en) * 2008-07-23 2017-11-28 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
EP3242666A1 (en) * 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US11497718B2 (en) * 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis

Also Published As

Publication number Publication date
KR20230106644A (ko) 2023-07-13
CN116887826A (zh) 2023-10-13
US20230414567A1 (en) 2023-12-28
IL302816A (en) 2023-07-01
CA3200998A1 (en) 2022-05-12
JP2023548474A (ja) 2023-11-17
WO2022099150A1 (en) 2022-05-12
EP4240349A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2023005342A (es) Métodos para tratar padecimientos relacionados con el receptor s1p1.
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2021009037A (es) Composiciones y metodos para el manejo de trastornos.
MX2022001295A (es) Inhibidores de kif18a.
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
BR112015022575A2 (pt) composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
EA202191519A1 (ru) Модуляторы trex1
BR112019001457A2 (pt) tratamento e prevenção de distúrbios do sono
JOP20210050A1 (ar) معدلات تعبير pnpla3
BR112021006398A2 (pt) tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
WO2018237379A3 (en) COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
ZA202001321B (en) Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
EP4087562A4 (en) METHODS OF TREATING S1P1 RECEPTOR-RELATED CONDITIONS
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
JOP20200291A1 (ar) معدلات التعبير عن apol1
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.